· ST-HF-01 · v2
This claim says statins fail to improve cardiovascular outcomes in people with weakened-pump (systolic) heart failure. The pieces of primary evidence this corpus actually allows to be scored all point the other way: a subgroup of a large rosuvastatin trial in ischemic systolic heart failure saw fewer cardiovascular events and fewer heart-failure hospitalisations [4], a large real-world cohort linked statin use to fewer deaths and hospitalisations [8], and a small short trial showed better heart function and symptoms [1]. None of these is strong enough to prove statins help, but none supports the claim that they do nothing. The one kind of study that could settle a flat 'no benefit' verdict, the overall result of the big neutral heart-failure trials, is mentioned only inside review and commentary articles [5], [18] that were set aside because they are not primary research. So the panel could not confirm the claim from what is scorable here, and noted this is a gap in the available corpus rather than proof the claim is wrong.
Within scorable primary research the signal runs against the claim. In the CORONA subgroup with hs-CRP >/= 2 mg/L, rosuvastatin was associated with nominally significant reductions in the primary outcome of cardiovascular death, myocardial infarction or stroke and reduced heart-failure hospitalisations (827 vs 1015 on placebo, p = 0.0044) [4]. In 24,598 adults with chronic heart failure, incident statin use was associated with lower death (adjusted hazard ratio 0.76, 95% CI 0.72-0.80) and lower heart-failure hospitalisation (0.79, 95% CI 0.74-0.85) [8]. A 14-week trial in 63 patients with nonischemic dilated cardiomyopathy showed improved ejection fraction (34 to 41%, P<0.05) and lower NYHA class with simvastatin [1]. The overall neutral CORONA and GISSI-HF primary-trial results appear only inside study-type-excluded reviews [5], [6], [18]. The contested point: The division is whether the absence of the neutral primary-trial result means the claim fails or merely cannot be tested: every includable primary paper [1], [4], [8] trends toward benefit, yet each is a subgroup, an observational cohort, or a surrogate endpoint, so none refutes the claim and none can carry it. The authoritative neutral evidence that would decide the direction survives only in the excluded reviews [5], [18].
All 18 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Statins, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The pivotal neutral primary-trial evidence (CORONA overall result and GISSI-HF) that would be needed to establish a negative claim is present only inside study-type-excluded reviews ([5], [18]); no includable primary paper reports it.
[4] is a retrospective hs-CRP subgroup of CORONA reporting 'nominally' significant benefit only in high-CRP patients — subgroup multiplicity and not the trial's overall result; it cannot be read as the whole-population finding in either direction.
Where it remains uncertain. The overall neutral primary-trial result needed to confirm a 'no reduction' claim is present only inside study-type-excluded reviews [5], [18], so the negative claim cannot be established from what is scorable.
Aleatory
[4] reports 'nominally' significant benefit in one hs-CRP subgroup, so chance across multiple subgroup comparisons cannot be excluded.
Epistemic
The overall CORONA and GISSI-HF primary-trial outcomes appear only in excluded reviews [5], [6], [18] and in no includable primary paper.
Inferential
[1] measures LVEF, NYHA, cytokines and BNP, not cardiovascular events, so its bearing on the claim is indirect.
The load-bearing papers from a corpus of 18, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Surrogate endpoints only (LVEF, NYHA, biomarkers), 14 weeks, n=63 — does not measure CV outcomes; indirect.
“Short-term statin therapy improves cardiac function, neurohormonal imbalance, and symptoms associated with idiopathic dilated cardiomyopathy.”
Panel auditInternal validity: low · scope of inference: Short-term effect of simvastatin on cardiac function and symptoms in symptomatic nonischaemic dilated cardiomyopathy.Key limitations: surrogate endpoints only · small n · short follow-up · no CV event data
Observational HF cohort associating statins with lower CV/mortality outcomes; runs against the claim but is confounded and not reduced-EF specific.
“incident statin use was associated with lower risks of death (age- and sex-adjusted rate of 14.5 per 100 person-years with statin therapy vs 25.3 per 100 person-years without statin therapy; adjusted hazard ratio, 0.76 [95% confidence interval, 0.72-0.80]) and hospitalization for heart failure”
Panel auditInternal validity: medium · scope of inference: Association of statin initiation with death and HF hospitalization in a general HF population without prior statin use.Key limitations: observational · EF not specified · confounding by indication
In-scope systolic ischemic HF RCT, but a retrospective subgroup showing benefit — tensions, rather than supports, the 'do not reduce' claim.
“In patients with a hsCRP >/= 2 mg/L, rosuvastatin treatment was associated with nominally statistically significant reductions in the primary outcome (cardiovascular death, myocardial infarction or stroke)”
Panel auditInternal validity: low · scope of inference: Effect of rosuvastatin in the elevated-hsCRP subgroup of ischaemic systolic HF patients in CORONA.Key limitations: retrospective subgroup · nominal significance only · benefit confined to high-CRP subgroup
3 of 18 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Scorable primary evidence tends against the claim while remaining too weak to refute it, and the definitive neutral RCT data survives only in study-type-excluded reviews, so the claim cannot be confirmed from this corpus.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Overall primary-trial result in reduced-EF HF. The claim is a negative universal that only a whole-population neutral or positive RCT result can confirm or refute, and no includable primary paper reports one. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: Admit, as primary research, placebo-controlled statin RCTs in reduced-EF systolic HF reporting the overall cardiovascular-outcome result, not only subgroups [4] or biomarker analyses [9].
Open question: Do statins change cardiovascular death, MI or stroke in the whole reduced-EF systolic heart-failure population, not just a high-CRP subgroup? Why it is still open: The only in-scope RCT datapoint [4] is a retrospective hs-CRP subgroup; the overall result is absent from includable primary research.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 26 Oct 2026 · protocol v0.19